A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma

Cancer

Volumn 97, Issue 3, 2003, Pages 537-544

  Tiersten, Amy D ^a   Nelsen, Caron ^a   Talbot, Susan ^a   Vahdat, Linda ^a   Fine, Robert ^a   Troxel, Andrea ^a   Brafman, Lois ^a   Shriberg, Laureen ^a   Antman, Karen ^a   Petrylak, Daniel P ^a  

^a NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

Breast carcinoma; Docetaxel; Estramustine; Metastatic

Indexed keywords

ACETYLSALICYLIC ACID; DALTEPARIN; DOCETAXEL; ESTRAMUSTINE; PACLITAXEL; WARFARIN;

ADULT; AGED; ANOREXIA; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; EPISTAXIS; ERYTHEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEMOPTYSIS; HOT FLUSH; HUMAN; HYPERGLYCEMIA; HYPOACUSIS; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; LIVER TOXICITY; METASTASIS; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SENSORY DYSFUNCTION; STOMATITIS; STROKE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; VAGINA BLEEDING; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; ESTRAMUSTINE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; QUALITY OF LIFE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TAXOIDS;

EID: 0037302155     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11082     Document Type: Article

References (29)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics 2001. CA Cancer J Clin. 2001;51:15-36.
2. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, et al., editors. Diseases of the breast. Philadelphia: Lippincott Williams and Wilkins, 2000:749.
3. Esteva FJ, Valero V, Pusztai L, et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist. 2001;6:133-146.
4. Ringel I, Horwitz SB. Studies with RP 56976 (taxotere), a semisynthetic analogue of taxol. J Natl Cancer Inst. 1991;83: 288-291.
5. Diax JF, Andreu JM. Assembly of purified GDP-tubulin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry and competition. Biochemistry. 1993; 32:2747-2755.
6. Schmidinger M, Budinsky AC, Wenzel C, et al. Docetaxel monotherapy in heavily pretreated metastatic breast cancer: a mulitcenter, community-based feasibility trial. Cancer Chemother Pharmacol. 2001;47:57-62.
7. Chan S, Friedrichs K, Noel D, et al. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group. J Clin Oncol. 1999;17:2341-2354.
8. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol. 1999;17:1413-1424.
9. Kreis W, Budman D, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33-38.
10. Williams JF, Muenchen HJ, Kamradt JM, et al. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate. 2000;44:275-278.
11. Bjork P, Forgren B, Gustafsson J-A, et al. Partial characterization and quantitation of a human prostatic estramustine binding protein. Cancer Res. 1982;39:5155-5164.
12. Bjork P, Ferno M, Ferno M, et al. Expression and partial characterization of estramustine binding protein in human breast cancer and malignant melanoma. Anticancer Res. 1991;11:1173-1182.
13. von Schoultz E, Bergenheim T, Grankvist K, et al. Estramustine binding protein in human brain tumor tissue. J Neurosurg. 1989;14:27-43.
14. Stearns M, Tew K. Antimicrotubule effects of estramustine, an antiprostate tumor drug. Cancer Res. 1985;45:3891-3897.
15. Wallin M, Deinum J, Hartley-Asp B. Estramustine phosphate inhibits microtubule assembly by binding to the microtubule associated proteins. Ann NY Acad Sci. 1986;466:423-425.
16. Panda D, Miller HP, Islam K, Wilson L. Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci USA. 1997;94:10560-10564.
17. Yang CPH, Shen H, Horwitz SB. Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst. 1994; 86:723-725.
18. Kreis W, Budman D, Fetten J, et al. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol. 1999;10:33-38.
19. Petrylak D, MacArthur R, O'Connor J, et al. Phase I trial of docetaxel with estramustine in androgen independent prostate cancer. J Clin Oncol. 1999;17:958-967.
20. Savarese DM, Halabi S, Hats V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol. 2001;19:2509-2516.
21. Simon R. Optimal two-stage designs for Phase II clinical trials. Control Clin Trials. 1989;10:1-10.
22. Alexander NC, Hancock AK, Masood MB, et al. Estracyst in advanced carcinoma of the breast: a Phase II study. Clin Radiol. 1979;30:139-147.
23. Wada T, Morikawa E, Houjou T, et al. Clinical evaluation of estramustine phosphate in the treatment of patients with advanced breast cancers. Jpn J Cancer Chemother. 1990;17: 1901-1904.
24. Valero V. Docetaxel as a single-agent therapy in metastatic breast cancer: clinical efficacy. Semin Oncol. 1997;24(4 Suppl 13):S13-1-S13-18.
25. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol. 1995;13:2643-2655.
26. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol. 1995;13: 2879-2885.
27. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol. 1995;13:2886-2894.
28. Levine M, Hirsch J, Gent M, et al. Double blind randomized trial of a very low dose wafarin for prevention of thrombo-embolism in Stage IV breast cancer. Lancet. 1997;343:886-889.
29. Levin MN. Prevention of thrombotic disorders in cancer patients undergoing chemotherapy. Thromb Haemost. 1997; 78:133-136.